Atlas Trials

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical trial NCT00868413 · COMPLETED

Trial details

NCT number
NCT00868413
Sponsor
AbbVie (prior sponsor, Abbott)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2009-11-01
Primary completion
2013-05-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.